Table 1 Patient characteristics. Values of the most recent CCP2-IgG plasma titer, EBNA-IgG plasma titer, and VCA-IgG plasma titer were determined by diagnostic testing. Of patients one to seven, PB was analyzed and depicted in Figs. 1A–C and 2D. From patient eight, we analyzed SF and the results are depicted in Supplementary Fig. 2. Disease activity was assessed by routine clinical assessment of 28 joints for pain and swelling and subsequent calculation of the DAS28(3v)-ESR
Patient | Age | Sex | Treatment at time of blood collection | CCP2-IgG titer (U/mL) | EBNA-IgG titer (U/mL) | VCA-IgG titer (U/mL) | Isolated ACPA cells per pool | Time since CCP2+ RA diagnosis | DAS28(3v)-ESR |
|---|---|---|---|---|---|---|---|---|---|
1 | 65 | F | Methotrexate | > 340 | 26,9 | 455 | 6 x 20 cells, 1 x 18 cells | 3 years and 3 months | 1,97 |
2 | 68 | M | Methotrexate + hydroxychloroquine | > 313 | > 600 | 742 | 1 x 20 cells, 1 x 18 cells | 2 years and 3 months | 1,82 |
3 | 79 | F | Methotrexate | > 340 | 161 | > 750 | 1 x 18 cells | 25 years | 1,97 |
4 | 69 | F | Prednisone | > 340 | 40,8 | 524 | 2 x 20 cells | 24 years | 5,11 |
5 | 75 | F | Etanercept | > 313 | 238 | > 750 | 2 x 20 cells | 27 years | 1,97 |
6 | 71 | F | Leflunomide | > 265 | 12,1 | > 750 | 1 x 10 cells | 5 years | 3,40 |
7 | 58 | M | Methotrexate | > 340 | > 600 | > 750 | 1 x 12 cells | 4 months | 2,16 |
8 | 49 | F | Methotrexate | > 340 | 272 | > 750 | 3 x 20 cells | 21 years | 3,84 |